Drug intelligence / Profile preview

S-9156

Development stage: Discontinued
Lead developer: Sonus Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

S-9156 is an experimental blood volume expander developed by Sonus Pharmaceuticals using its proprietary TOCOSOL emulsion technology. The TOCOSOL platform utilizes Vitamin E (alpha-tocopherol) to create stable, sub-micron injectable emulsions. S-9156 was specifically designed for the treatment of hypovolemia, acting as a plasma volume expander to restore circulatory stability. The development of S-9156 was part of Sonus's broader effort to apply its emulsion technology beyond oncology, though the project was ultimately discontinued following the company's shift in focus and subsequent merger with OncoGenex Pharmaceuticals in 2008.

Other names: TOCOSOL Blood Volume Expander

Beyond the preview

Go deeper on S-9156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-9156.

Explore the full profile